Witnessing the stock’s movement on the chart, on Thursday, Allogene Therapeutics Inc (NASDAQ: ALLO) had a quiet start as it plunged -5.41% to $1.05, before settling in for the price of $1.11 at the close. Taking a more long-term approach, ALLO posted a 52-week range of $0.86-$3.78.
It was noted that the giant of the Healthcare sector posted annual sales growth of 6.26% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 6.26%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 28.10%. This publicly-traded company’s shares outstanding now amounts to $220.13 million, simultaneously with a float of $153.74 million. The organization now has a market capitalization sitting at $232.98 million. At the time of writing, stock’s 50-day Moving Average stood at $1.2142, while the 200-day Moving Average is $1.3960.
Allogene Therapeutics Inc (ALLO) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Allogene Therapeutics Inc’s current insider ownership accounts for 30.71%, in contrast to 60.77% institutional ownership. According to the most recent insider trade that took place on Oct 21 ’25, this organization’s CHIEF FINANCIAL OFFICER sold 36,744 shares at the rate of 1.26, making the entire transaction reach 46,169 in total value, affecting insider ownership by 1,276,796.
Allogene Therapeutics Inc (ALLO) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year. Allogene Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 28.10% and is forecasted to reach -0.88 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 13.60% through the next 5 years, which can be compared against the 6.26% growth it accomplished over the previous five years trading on the market.
Allogene Therapeutics Inc (NASDAQ: ALLO) Trading Performance Indicators
Let’s observe the current performance indicators for Allogene Therapeutics Inc (ALLO). It’s Quick Ratio in the last reported quarter now stands at 8.92.
In the same vein, ALLO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.11, a figure that is expected to reach -0.23 in the next quarter, and analysts are predicting that it will be -0.88 at the market close of one year from today.
Technical Analysis of Allogene Therapeutics Inc (ALLO)
Going through the that latest performance of [Allogene Therapeutics Inc, ALLO]. Its last 5-days volume of 2.07 million was inferior to the volume of 4.03 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 17.77% While, its Average True Range was 27.36.
Raw Stochastic average of Allogene Therapeutics Inc (ALLO) in the period of the previous 100 days is set at 9.32%, which indicates a major rise in contrast to 0.00% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.0714 that was lower than 0.0867 volatility it exhibited in the past 100-days period.
